文献速递乳房整形与再造创面修复

脂质体布比卡因在整形与重建手术中的成本最小化分析

A Cost-Minimization Analysis Evaluating the Use of Liposomal Bupivacaine in Reconstructive Plastic Surgery Procedures.
PubMed 文献 · Plast Reconstr Surg · 2019-01-01

本研究基于Vizient临床数据库,回顾2016年7月至2017年7月多家医院共958例整形与重建手术病例,其中239例(25%)使用脂质体布比卡因。结果显示使用该药者住院时间、总费用与直接费用及30天再入院率均更低,提示其可能改善系统层面的经济性。

要点

  • 使用脂质体布比卡因者住院时间9.2天对5.8天,总费用与直接费用均更低。
  • 30天再入院率为4%对0%,使用组更低;7天与14天再入院率两组相似。
  • 结论提示其或可降低腹部与乳房重建手术的住院时间、费用与30天再入院率。

核心结论

  • 脂质体布比卡因可能有助于降低腹部与乳房重建手术的住院时间、住院费用和30天再入院率。
  • 从系统视角看,这可能带来有利的经济学特征。
  • 在向价值付费转型中,关注可定义患者流程整体的价值测量与改进很重要。

研究设计与样本

  • 基于Vizient临床数据库/资源管理器的回顾性分析,纳入2016年7月1日至2017年7月1日参与医院的整形手术病例。
  • 共958例符合纳入标准,其中239例(25%)使用脂质体布比卡因。
  • 纳入术式包括腹壁成形、腹壁重建、乳房切除加即刻组织扩张器置入、乳房切除加直接假体再造、自体乳房再造和隆乳。

主要发现

  • 使用脂质体布比卡因者住院时间为9.2天,未使用者为5.8天。
  • 使用组总费用为39,531美元,未使用组为28,021美元;直接费用分别为17,561美元和23,960美元。
  • 30天再入院率为4%对0%,使用组更低。
  • 7天和14天再入院率两组相似。

临床怎么用

  • 在腹部与乳房重建手术的术后疼痛管理中,可考虑脂质体布比卡因以缩短住院时间并降低费用。
  • 决策时应结合本机构费用结构与再入院数据评估其经济价值。

局限性

  • 为基于国家理赔/临床数据库的回顾性成本最小化分析,可能存在混杂与选择偏倚。
  • 未报告具体统计检验、P值或置信区间,因果推断受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postsurgical pain management is critical to patient satisfaction and value. Several studies have evaluated liposomal bupivacaine in postoperative pain management protocols; however, its economic feasibility remains undefined. This study analyzes the economic impact of liposomal bupivacaine using a national claims database to assess postoperative clinical and financial outcomes in plastic and reconstructive procedures. METHODS: The Vizient Clinical Data Base/Resource Manager electronic database was reviewed for plastic surgery procedures (i.e., abdominoplasty, abdominal wall reconstruction, mastectomy with immediate tissue expander placement, mastectomy with direct-to-implant reconstruction, autologous breast reconstruction, and augmentation mammaplasty) at participating hospitals from July 1, 2016, to July 1, 2017. The main outcome measures were the length of stay; 7-, 14-, and 30-day readmission rates; and direct and total costs observed. RESULTS: During the study period, 958 total cases met inclusion criteria. Liposomal bupivacaine was used in 239 cases (25 percent). Compared with cases that did not use liposomal bupivacaine, liposomal bupivacaine cases had a decreased length of stay (9.2 days versus 5.8 days), decreased cost (total cost, $39,531 versus $28,021; direct cost, $23,960 versus $17,561), and lower 30-day readmission rates (4 percent versus 0 percent). The 14- and 7-day readmission rates were similar between the two groups. CONCLUSIONS: The use of liposomal bupivacaine may contribute to a reduction in length of stay, hospital costs, and 30-day readmission rates for abdominal and breast reconstructive procedures, which could contribute to a favorable economic profile from a system view. Focusing on the measurement and improvement of value in the context of whole, definable, patient processes will be important as we transition to value-based payments.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Little A, Brower K, Keller D, et al. A Cost-Minimization Analysis Evaluating the Use of Liposomal Bupivacaine in Reconstructive Plastic Surgery Procedures. Plast Reconstr Surg. 2019. PMID: 30730499. doi:10.1097/PRS.0000000000005435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。